Early-stage data on Exelixis' colorectal cancer drug zanzalintinib appears to have disappointed investors
https://seekingalpha.com/news/4397493-exelixis-falls-8-percent-abstract-colorectal-cancer-candidate-zanzalintinib
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.